Novartis Investigative Site 86179 Augsburg (Bayern) GermanyAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 13353 Berlin (Berlin) GermanyAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 45147 Essen (Nordrhein-Westfalen) GermanyAktiv, nicht rekrutierend» Google-Maps
Novartis Investigative Site 20246 Hamburg (Hamburg) GermanyAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 50937 Koeln (Nordrhein-Westfalen) GermanyAktiv, nicht rekrutierend» Google-MapsPhoenix Children's Hospital . 85016 Phoenix United StatesAktiv, nicht rekrutierend» Google-MapsChildrens National Hospital CQTI571A2306 20010 Washington United StatesAktiv, nicht rekrutierend» Google-MapsNicklaus Childrens Hospital 33155 Miami United StatesAktiv, nicht rekrutierend» Google-MapsIndiana University School of Medicine . 46202-2810 Indianapolis United StatesAktiv, nicht rekrutierend» Google-MapsJohns Hopkins University IDS Pharmacy 21287 Baltimore United StatesAktiv, nicht rekrutierend» Google-MapsDana Farber Cancer Institute . 02215 Boston United StatesAktiv, nicht rekrutierend» Google-MapsUniversity of Minnesota . 55455 Minneapolis United StatesAktiv, nicht rekrutierend» Google-MapsMemorial Sloan Kettering Cancer Center 10065 New York United StatesRekrutierend» Google-Maps Ansprechpartner: Jessica Sollitto Phone: 212-639-3112 E-Mail: dunkel@MSKCC.ORG» Ansprechpartner anzeigenCinn Children Hosp Medical Center 45229-3039 Cincinnati United StatesAktiv, nicht rekrutierend» Google-MapsSt Jude Children's Research Hospital . 38105 Memphis United StatesAktiv, nicht rekrutierend» Google-MapsTexas Children's Hospital 77030 Houston United StatesAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site C1428AQK Caba ArgentinaAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 2010 Darlinghurst AustraliaAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 3052 Parkville AustraliaAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 1200 Bruxelles BelgiumAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 14784 400 Barretos BrazilAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 04829-310 Sao Paulo BrazilAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 08270-070 Sao Paulo BrazilAbgeschlossen» Google-MapsNovartis Investigative Site V6H 3V4 Vancouver CanadaAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site M5G 1X8 Toronto CanadaAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site H3T 1C5 Montreal CanadaAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 613 00 Brno CzechiaAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 150 06 Praha 5 CzechiaAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site DK-2100 Copenhagen DenmarkAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 33521 Tampere FinlandAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 35203 Rennes FranceAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 29609 Brest Cedex FranceZurückgezogen» Google-MapsNovartis Investigative Site 13885 Marseille Cedex 05 FranceAbgeschlossen» Google-MapsNovartis Investigative Site 75231 Paris FranceAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 54511 Vandoeuvre Les Nancy FranceAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 94800 Villejuif FranceAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 49202 Petach-Tikva IsraelAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 50139 Firenze ItalyAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 16147 Genova ItalyAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 20133 Milano ItalyAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 00165 Roma ItalyAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 10126 Torino ItalyAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 157-8535 Setagaya-ku JapanAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 534-0021 Osaka JapanAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 3584 Utrecht NetherlandsAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 117198 Moscow Russian FederationAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 28009 Madrid SpainAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 46026 Valencia SpainAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site 17176 Stockholm SwedenAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site SM2 5PT Sutton United KingdomAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site L12 2AP Liverpool United KingdomAktiv, nicht rekrutierend» Google-MapsNovartis Investigative Site WC1N 3JH London United KingdomAktiv, nicht rekrutierend» Google-Maps
1. Number of participants with Adverse Events and Serious Adverse Events (SAEs) (Time Frame - Baseline up to approximately 7 years): To assess the long-term safety of treatment with dabrafenib, trametinib or the combination.
Secondary outcome:
1. Percentage of participants with height (measured by cm or in) changes over time (Time Frame - Baseline up to approximately 7 years): Developmental monitoring: Serial measurements of height will be collected throughout the study
2. Percentage of participants with weight (measured by kg or lb) changes over time (Time Frame - Baseline up to approximately 7 years): Developmental monitoring: Serial measurements of weight will be collected throughout the study
3. Percentage of participants with skeletal maturation (measured by bone age on x-ray or MRI) changes over time (Time Frame - Baseline up to approximately 7 years): Developmental monitoring: Serial measurements of skeletal maturation will be collected throughout the study
4. Percentage of participants with sexual maturation (measured by tanner staging criteria) changes over time (Time Frame - Baseline up to approximately 7 years): Developmental monitoring: Serial measurements of sexual maturation will be collected throughout the study
5. Percentage of participants with cardiac function (measured by ECG) changes over time (Time Frame - Baseline up to approximately 7 years): Developmental monitoring: Serial measurements of cardiac function will be collected throughout the study
6. Clinical Benefit (measured by CT/MRI) (Time Frame - Baseline up to approximately 7 years): Disease specific clinical benefit, as determined by investigator using institutional standard of care. Investigator will measure tumor response based on the Response Assessment used for the subject in the parent protocol (Response Assessment in Neuro-Oncology (RANO) criteria for solid tumors, RECIST, NF1 Volumetric, Neuroblastoma, or LCH criteria).